Class Cert. In Avandia MDL Undone For Lacking Stats
The Third Circuit undid class certification for a group of health plans claiming GlaxoSmithKline deceptively marketed its diabetes drug Avandia, with a panel majority ruling Tuesday the plans needed stronger statistical...To view the full article, register now.
Already a subscriber? Click here to view full article